Local treatment of primary and secondary bacterial skin infections including impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds/burns.
Treatment of superficial eye infections.
Action⬆⬇
Inhibits bacterial protein synthesis.
Therapeutic effects:
Resolution of localized bacterial infections.
Not active against Gram-negative organisms; active against Staphylococci, Streptococci, and Corynebacterium.
Pharmacokinetics⬆⬇
Absorption: Unknown.
Distribution: Systemically absorbed drug crosses the placenta and enters breast milk.
Metabolism/Excretion: Absorbed drug is extensively metabolized.
Half-Life: 5–6 hr.
Time/Action Profile⬆⬇
ROUTE
ONSET
PEAK
DURATION
Top
unknown
unknown
6–8 hr
Ophth
unknown
unknown
12 hr
Contraind./Precautions⬆⬇
Contraindicated in:
Hypersensitivity to fusidic acid or other components of the formulation (topical ointment contains lanolin).
Use Cautiously in:
OB: Potential benefits should be weighed against the possible hazards to the fetus (crosses the placenta);
Lactation: Safe use during breastfeeding has not been established (enters breast milk).
Adv. Reactions/Side Effects⬆⬇
Derm: mild local irritation
Interactions⬆⬇
Drug-drug:
None noted.
Route/Dosage⬆⬇
(Adults and Children ): Apply to affected area 3–4 times daily.
(Adults and Children ): One drop into conjunctival sac of both eyes every 12 hr for 7 days.
Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.
Implementation⬆⬇
Do not confuse topical product with ophthalmic product.
Consult health care professional for proper cleansing technique before applying medication. Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by health care professional.